Targeting tumor cells based on phosphodiesterase 3A (PDE3A) expression

JOINT EVENT:19^th Euro Congress on Cancer Science and Therapy & 25^th Cancer Nursing & Nurse Practitioners Conference

July 17-19, 2017 Lisbon, Portugal

Madiha Nazir

Uppsala University, Sweden

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

We and others have previously reported on a correlation between high phosphodiesterase 3A (PDE3A) expression and selective sensitivity to phosphodiesterase inhibitors. This indicates that PDE3A could serve both as drug target and biomarker of sensitivity to PDE3A inhibition. In our project, we explored publicly available gene expression data to identify cell lines, of various origins, with high PDE3A expression. The identified cell lines showed marked in vitro sensitivity to phosphodiesterase inhibitors (i.e. zardaverine and quazinone) when compared with cell lines with low PDE3A expression. Immunofluorescence and immunohistochemical staining were in agreement with PDE3A mRNA expression, providing suitable alternatives for biomarker analysis of clinical tissue specimens. Moreover, we have demonstrated that primary cells from patients with ovarian carcinoma show great variability in PDE3A protein expression and that level of PDE3A expression seems to be correlated with sensitivity to PDE3A inhibition. Finally, we have demonstrated that a number of various solid tumor samples stain positively for PDE3A protein, rendering PDE3A expression a promising drug target and biomarker of PDE3A inhibition sensitivity.

Biography :

Madiha Nazir is currently doing her PhD in Cancer Pharmacology and Computational Medicine from Uppsala University, Sweden. Her thesis work mainly focuses on drug repositioning for cancer treatment.

Email: madiha.nazir@medsci.uu.se